SALT LAKE CITY, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the substantial completion of its strategic ...

In a report released on August 7, Puneet Souda from Leerink Partners maintained a Buy rating on Myriad Genetics (MYGN – Research Report), with a price target of $35.00. Puneet Souda has given his Buy ...

These mutations improve biocontainment, transformation stability, and overall performance in genetic engineering of plants. Complementing the strains, researchers also developed new plasmids and a ...

B, as a powerful regulator that enhances wheat’s regeneration efficiency by balancing cytokinin levels and activating regeneration-related genes.

A pioneering scientist who made global breakthroughs in the use of genetic technologies for crop plants has been awarded one ...